Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
Ohio State University Comprehensive Cancer Center
PharmaEssentia Japan K.K.
Incyte Corporation
Protagonist Therapeutics, Inc.
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
PharmaEssentia Japan K.K.
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Vanderbilt-Ingram Cancer Center
Ottawa Hospital Research Institute
Protagonist Therapeutics, Inc.
University Health Network, Toronto
M.D. Anderson Cancer Center
Thomas Jefferson University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Odense University Hospital
Hoffmann-La Roche
Northwestern University
Roswell Park Cancer Institute
Novartis
Icahn School of Medicine at Mount Sinai
AOP Orphan Pharmaceuticals AG
H. Lee Moffitt Cancer Center and Research Institute
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Novartis
Canadian Cancer Trials Group
Fred Hutchinson Cancer Center
Mayo Clinic
Italfarmaco
Italfarmaco
Mayo Clinic
Roswell Park Cancer Institute
Icahn School of Medicine at Mount Sinai
Italfarmaco
Novartis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Swiss Cancer Institute
Incyte Corporation
University of Illinois at Chicago
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Eli Lilly and Company
Incyte Corporation
AOP Orphan Pharmaceuticals AG
OHSU Knight Cancer Institute